“I believed in the power of PhysioPD when I first saw it twenty-five years ago, I’ve had a passion for it ever since, and now we have enough experience that I know it works.”


About Rosa & Co
Rosa was founded in 2002 and remains an employee-owned, science-focused, and client-friendly firm. Today, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies.
Rosa's ForecastMD Platforms, which offers a credible methodology for determining expected physician uptake for healthcare products, was started by Bill Brastow, Ph.D., in 2005. Our models have helped shape first-in-class markets including novel therapy combinations for HIV and molecular diagnostic tests for Oncology.
Rosa’s staff bring more than a century of aggregate experience in applying modeling to the inherent challenges faced by drug developers and have authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications.
Rosa Leadership in the Community
-
Host Worldwide Webinar Series: Impact of Modeling & Simulation in Drug Development
Presentations from the pharmaceutical industry, academia, and regulatory agencies -
International Society of Pharmacometrics
Chair of the QSP Special Interest Group
Member of the Variability, Uncertainty, and Error in QSP Models Working Group
Co-Chair of the Integrating QSP and Machine Learning Working Group
Member of the Immuno-Oncology Working Group
Former Member of the QSP Workflows and Methodologies Working Group
Former Chair of the QSP in Regulatory Interactions Working Group
Former Secretary of the QSP SIG -
Strategic Cooperation Agreement with MathWorks®, provider of MATLAB®, and SimBiology®
Recent Highlights
The International Society of Pharmacometrics has announced the Outstanding Research Manuscript Award for 2023 is “Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clini... Read More
Rosa will present a talk and a poster at the Fourteenth American Conference on Pharmacometrics (ACoP14). Dr. Friedrich will present “QSP Modelers – Take Your Data Seriously, Not Literally!” during the Roller Coaster 2 session on Wednesday, 11/8/23. D... Read More
Rosa’s Brian Schneider will attend the Health Economics & Outcomes Research (HEOR) Summit December 12 - 14, 2023 in Philadelphia, PA. https://heor-summit.com/... Read More
Upcoming Events
-
ACoP14 2023
November 5 - 8, 2023Fourteenth American Conference on Pharmacometrics (ACoP14). https://www.go-acop.org/National Harbor, MD -
Proventa International’s 10th Annual Clinical Operations Strategy Meeting
November 9, 2023Rosa's Brian Schneider and Matt Marano will run a Roundtable. More information is available at https://proventainternational.com/events/clinical/usa-east/boston/clinical-operations-meeting-east-coast-november-2023/Le Meridien Cambridge, Massachusetts, USA -
Health Economics & Outcomes Research Summit
December 12 - 14, 2023The Health Economics & Outcomes Research Summit is a focused gathering to advance tactical and strategic conversations, leveraging innovative methods to demonstrate the value proposition of new drugs to secure formulary and market access. https://heor-summit.com/Philadelphia, PA
Recent Events
-
PAGE 2023
June 27- 30, 2023Rosa presented two posters at the Population Approach Group Europe (PAGE) 2023 Meeting.A Coruña, Spain -
Creating a Roadmap to Quantitative Systems Pharmacology-informed Rare Disease Drug Development
May 11, 2023The U.S. Food and Drug Administration (FDA)- in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI)- will host a one-day virtual public workshop entitled “Creating a Roadmap to Quantitative Systems Pharmacology-informed Rare Disease Drug Development” For registration information, see https://cersi.umd.edu/event/17946/creating-a-roadmap-to-quantitative-systems-pharmacology-informed-rare--disease-drug-development.Virtual
The Rosa & Co. Executive Team
-
Ron Beaver, PhD
Founder, Chairman, and CEO
Dr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a...
Read MoreDr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a management consultancy and venture incubator firm. PSG incubated StarMine, a unique quantitative-modeling financial services company (subsequently acquired by Thomson Reuters). Prior to PSG, Dr. Beaver was an associate at Strategic Decisions Group (SDG). In the early 1990s, he closely observed the advancement of predictive biosimulation software which led to the spin-off of Entelos, Inc., the first-generation PhysioPD-style company (acquired by Rosa in 2014). Dr. Beaver holds a PhD in Engineering from Stanford University and a BA from Simpson College, on whose Board of Trustees he served.
Collapse -
Matt Marano
Chief Commercial Officer
Mr. Marano has over 30 years of experience in the life sciences industry, both as a researcher and as a sales and business development professional. Prior to joining Rosa in 2017, Mr. Marano held worldwide business development leadership roles at SolveBio, a developer of actionable information assets that drive precision medicine, and Gen9 (now part of Ginkgo Bioworks), a leading synthetic biology solutions provider. Prior to Gen9, Mr. Marano created and expanded the global commercial presence...
Read MoreMr. Marano has over 30 years of experience in the life sciences industry, both as a researcher and as a sales and business development professional. Prior to joining Rosa in 2017, Mr. Marano held worldwide business development leadership roles at SolveBio, a developer of actionable information assets that drive precision medicine, and Gen9 (now part of Ginkgo Bioworks), a leading synthetic biology solutions provider. Prior to Gen9, Mr. Marano created and expanded the global commercial presence for a number of industry-leading life sciences firms, including Archimedes Inc. (acquired by Evidera), BioTrove’s RapidFire business unit (now part of Agilent Technologies Inc.), Ardais Corporation, and Molecular Dynamics. Mr. Marano began his career as a bench scientist at BASF Bioresearch Corporation (now part of AbbVie), and was a member of the development team for Humira®, one of a class of medications called biological response modifiers. Mr. Marano received his BS in Biology from Providence College, and completed graduate-level course work in Molecular Biology at Providence College and Harvard University Extension School.
Collapse -
Christina Friedrich, PhD
Chief Engineer, PhysioPD
Dr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system dy...
Read MoreDr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system dysfunctions and inflammatory processes. While at Rosa, Dr. Friedrich developed and published the first peer-reviewed journal article on the qualification of mechanistic mathematical models. Before Rosa, Dr. Friedrich was the Director of Core Product Development at Entelos, Inc., the first-generation leader in PhysioPD-style models. Dr. Friedrich has spearheaded numerous modeling methodologies and contributed to foundational patents, including on the use of virtual patients and populations to explore biological variability and uncertainty, and on the identification of biomarkers. Dr. Friedrich completed her BS at MIT and a PhD in Management Science and Engineering at Stanford University.
Collapse -
Mike Reed, PhD
Chief Scientist, PhysioPD
Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been presen...
Read MoreDr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide. Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes. Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models.
Collapse -
Brian Schneider
Vice President of Business
For over 24 years, Mr. Schneider has been working with life science organizations at all stages of the drug development pipeline. By asking questions and bringing insights, he has developed trusting relationships with clients attempting to make the best decisions with the most relevant data. Prior to joining Rosa in 2023, Mr. Schneider has sold reagents, instrumentation and services in a variety of markets including microscopy, image analysis, tissue diagnostics, immuno-assays, DNA synthesis and...
Read MoreFor over 24 years, Mr. Schneider has been working with life science organizations at all stages of the drug development pipeline. By asking questions and bringing insights, he has developed trusting relationships with clients attempting to make the best decisions with the most relevant data. Prior to joining Rosa in 2023, Mr. Schneider has sold reagents, instrumentation and services in a variety of markets including microscopy, image analysis, tissue diagnostics, immuno-assays, DNA synthesis and genome engineering. Mr. Schneider holds an S.M. in Biology from MIT and a B.S. in Biochemistry from the University of Rochester in NY.
Collapse -
Robert W. Singer
Principal, Rosa ForecastMD
Rob Singer brings over 20 years of experience in the healthcare market research field to Rosa & Co. Prior to joining Rosa in 2020, Rob conducted market research projects for Biotech, Pharmaceutical, Medical Device and Diagnostic Companies with Promedica and Cello Health Insight. During that time, Rob had the opportunity to partner with Bill Brastow on numerous Rosa ForecastMD projects for Promedica and Cello clients. Before moving into market research, Rob began his career in hospital and fi...
Read MoreRob Singer brings over 20 years of experience in the healthcare market research field to Rosa & Co. Prior to joining Rosa in 2020, Rob conducted market research projects for Biotech, Pharmaceutical, Medical Device and Diagnostic Companies with Promedica and Cello Health Insight. During that time, Rob had the opportunity to partner with Bill Brastow on numerous Rosa ForecastMD projects for Promedica and Cello clients. Before moving into market research, Rob began his career in hospital and field sales positions for Rhone-Poulenc Rorer (now Sanofi) and Forest Pharmaceuticals (now Allergan). Rob received his BS in Marketing from San Francisco State University and is based in the San Francisco Bay Area.
Collapse